Should EMA's Conditional Nod for ANKTIVA in High-Risk Bladder Cancer Require Action From ImmunityBio (IBRX) Investors? [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
with BCG, to treat BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ in adults across the EU. This marks the first EMA-recommended immunotherapy for this high-risk bladder cancer setting that activates NK cells, T cells, and memory T cells, potentially offering an alternative to radical surgery for patients whose disease does not respond to BCG. With this regulatory milestone and ANKTIVA's novel immune-activating profile, we'll explore how the news reshapes ImmunityBio's investment narrative. The latest GPUs need a type of rare earth metal called Dysprosium and there are only 37 companies in the world exploring or producing it . Find the list for free. For anyone considering ImmunityBio, the core belief is that ANKTIVA can evolve from a single approved bladder cancer product into a broader immune-oncology and immune-restoration platform, while the company closes its funding gap. The EMA's conditional marketing nod for ANKTIVA in BCG-unresponsive NMIBC CIS s
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio (IBRX) Climbs 7.76% on Europe Expansion [Yahoo! Finance]Yahoo! Finance
- ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..MarketBeat
- ImmunityBio, Novo, Moderna among winners of EU drug recommendations this week [Seeking Alpha]Seeking Alpha
- ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in EuropeBusiness Wire
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 12/12/25 - Form 8-K
- 11/10/25 - Form SCHEDULE
- 11/5/25 - Form 8-K
- IBRX's page on the SEC website